Top

Published in:

01-04-2012 | Preclinical Study

A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity

Authors: Ensel Oh, Yoon-La Choi, Taesung Park, Seungyeoun Lee, Seok Jin Nam, Young Kee Shin

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Abstract

A model for a more precise prognosis of the risk of relapse is needed to avoid overtreatment of lymph node-negative breast cancer patients. A large derivation data set (n = 684) was generated by pooling three independent breast cancer expression microarray data sets. Two major prognostic factors, proliferation and immune response, were identified among genes showing significant differential expression levels between the good outcome and poor outcome groups. For each factor, four proliferation-related genes (p-genes) and four immunity-related genes (i-genes) were selected as prognostic genes, and a prognostic model for lymph node-negative breast cancer patients was developed using a parametric survival analysis based on the lognormal distribution. The p-genes showed a predominantly negative correlation (coefficient: −0.603) with survival time, while the i-genes showed a positive correlation (coefficient: 0.243), reflecting the beneficial effect of the immune response against deleterious proliferative activity. The prognostic model shows that approximately 54% of lymph node-negative breast cancer patients were predicted to be distant metastasis-free for more than 5 years with at least 85% survival probability. The prognostic model showed a robust and high prognostic performance (HR 2.85–3.45) through three external validation data sets. Based on the integration of proliferation and immunity, the new prognostic model is expected to improve clinical decision making by providing easily interpretable survival probabilities at any time point and functional causality of the predicted prognosis with respect to proliferation and immune response.

Available only for authorised users

Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB et al (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2:E7PubMedCrossRef

van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef

van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef

Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679PubMed

Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M et al (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183–1192PubMedCrossRef

Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12:631–635PubMedCrossRef

Paik S, Shak S, Tang G, Kim C, Baker J et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262–272PubMedCrossRef

Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953–R964PubMedCrossRef

10.

Miller LD, Smeds J, George J, Vega VB, Vergara L et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550–13555PubMedCrossRef

11.

Bild AH, Yao G, Chang JT, Wang Q, Potti A et al (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353–357PubMedCrossRef

12.

Teschendorff AE, Naderi A, Barbosa-Morais NL, Pinder SE, Ellis IO et al (2006) A consensus prognostic gene expression classifier for ER positive breast cancer. Genome Biol 7:R101PubMedCrossRef

13.

Desmedt C, Piette F, Loi S, Wang Y, Lallemand F et al (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13:3207–3214PubMedCrossRef

14.

Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721–728PubMedCrossRef

15.

Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S et al (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26:729–735PubMedCrossRef

16.

Ein-Dor L, Kela I, Getz G, Givol D, Domany E (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21:171–178PubMedCrossRef

17.

Michiels S, Koscielny S, Hill C (2005) Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365:488–492PubMedCrossRef

18.

Kim SY (2009) Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics 10:147PubMedCrossRef

19.

Hummel M, Metzeler KH, Buske C, Bohlander SK, Mansmann U (2008) Association between a prognostic gene signature and functional gene sets. Bioinformatics Biol Insights 2:329–341

20.

Pfeffer U, Romeo F, Noonan DM, Albini A (2009) Prediction of breast cancer metastasis by genomic profiling: where do we stand? Clin Exp Metastasis 26:547–558PubMedCrossRef

21.

Ein-Dor L, Zuk O, Domany E (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 103:5923–5928PubMedCrossRef

22.

van Vliet MH, Reyal F, Horlings HM, van de Vijver MJ, Reinders MJ et al (2008) Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. BMC Genomics 9:375PubMedCrossRef

23.

Yasrebi H, Sperisen P, Praz V, Bucher P (2009) Can survival prediction be improved by merging gene expression data sets? PLoS One 4:e7431PubMedCrossRef

24.

Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569PubMedCrossRef

25.

Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE et al (2008) A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 10:R93PubMedCrossRef

26.

Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M et al (2007) Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer 7:182PubMedCrossRef

27.

Kim SY, Kim YS (2008) A gene sets approach for identifying prognostic gene signatures for outcome prediction. BMC Genomics 9:177PubMedCrossRef

28.

Thomassen M, Tan Q, Kruse TA (2008) Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer. BMC Cancer 8:394PubMedCrossRef

29.

Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A et al (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:5405–5413PubMedCrossRef

30.

Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246PubMedCrossRef

31.

Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F et al (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239PubMedCrossRef

32.

Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T et al (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116:303–309PubMedCrossRef

33.

Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F et al (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4111–4119PubMedCrossRef

34.

Dai M, Wang P, Boyd AD, Kostov G, Athey B et al (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33:e175PubMedCrossRef

35.

Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B et al (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31:e15PubMedCrossRef

36.

Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116–5121PubMedCrossRef

37.

Hougaard P (1999) Fundamentals of survival data. Biometrics 55:13–22PubMedCrossRef

38.

Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716–723CrossRef

39.

Garidou L, Laffont S, Douin-Echinard V, Coureau C, Krust A et al (2004) Estrogen receptor alpha signaling in inflammatory leukocytes is dispensable for 17beta-estradiol-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 173:2435–2442PubMed

40.

Schmidt M, Hengstler JG, von Torne C, Koelbl H, Gehrmann MC (2009) Coordinates in the universe of node-negative breast cancer revisited. Cancer Res 69:2695–2698PubMedCrossRef

41.

Calabro A, Beissbarth T, Kuner R, Stojanov M, Benner A et al (2009) Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat 116:69–77PubMedCrossRef

42.

Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518–527PubMedCrossRef

43.

Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11:R7PubMedCrossRef

44.

Mould RF, Boag JW (1975) A test of several parametric statistical models for estimating success rate in the treatment of carcinoma cervix uteri. Br J Cancer 32:529–550PubMedCrossRef

45.

Rutqvist LE, Wallgren A, Nilsson B (1984) Is breast cancer a curable disease? A study of 14,731 women with breast cancer from the Cancer Registry of Norway. Cancer 53:1793–1800PubMedCrossRef

46.

Boag JW (1949) Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Royal Stat Soc 11:15–44

47.

Tai P, Yu E, Shiels R, Tonita J (2005) Long-term survival rates of laryngeal cancer patients treated by radiation and surgery, radiation alone, and surgery alone: studied by lognormal and Kaplan-Meier survival methods. BMC Cancer 5:13PubMedCrossRef

48.

Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP et al (2009) Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 27:4103–4108PubMedCrossRef

49.

Potti A, Dressman HK, Bild A, Riedel RF, Chan G et al (2006) Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294–1300PubMedCrossRef

50.

Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M et al (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial. Lancet Oncol 8:1071–1078PubMedCrossRef

51.

Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A et al (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570–580PubMedCrossRef

52.

Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS et al (2007) Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350–4357PubMedCrossRef

Title: A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity
Authors: Ensel Oh
Yoon-La Choi
Taesung Park
Seungyeoun Lee
Seok Jin Nam
Young Kee Shin
Publication date: 01-04-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1626-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer

Outcomes of a weight loss intervention among rural breast cancer survivors

Targeting low molecular weight cyclin E (LMW-E) in breast cancer

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways

ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer